Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 55

1.

Transforming an Academic Radiochemistry Facility for Positron Emission Tomography Drug cGMP Compliance.

Zhu S, Mosessian S, Kroeger K, Sadeghi S, Slavik R, Kinloch S, Moore M, Allen-Auerbach M, Czernin J, Phelps M.

Mol Imaging Biol. 2019 Jun 25. doi: 10.1007/s11307-019-01395-6. [Epub ahead of print]

PMID:
31240531
2.

Solitary Mucinous Prostate Adenocarcinoma Lung Metastasis Detected by 68Ga-PSMA-11 PET/CT.

Polverari G, Ceci F, Allen-Auerbach M, Gupta P, Fishbein MC, Reiter RE, Lee JM, Hope TA, Carroll RM, Czernin J, Calais J.

Clin Genitourin Cancer. 2019 Feb;17(1):e53-e55. doi: 10.1016/j.clgc.2018.09.003. Epub 2018 Sep 7. No abstract available.

PMID:
30293922
3.

Quantitative bone scan lesion area as an early surrogate outcome measure indicative of overall survival in metastatic prostate cancer.

Brown MS, Kim GHJ, Chu GH, Ramakrishna B, Allen-Auerbach M, Fischer CP, Levine B, Gupta PK, Schiepers CW, Goldin JG.

J Med Imaging (Bellingham). 2018 Jan;5(1):011017. doi: 10.1117/1.JMI.5.1.011017. Epub 2018 Jan 11.

4.

Impact of 68Ga-PSMA-11 PET/CT on the Management of Prostate Cancer Patients with Biochemical Recurrence.

Calais J, Fendler WP, Eiber M, Gartmann J, Chu FI, Nickols NG, Reiter RE, Rettig MB, Marks LS, Ahlering TE, Huynh LM, Slavik R, Gupta P, Quon A, Allen-Auerbach MS, Czernin J, Herrmann K.

J Nucl Med. 2018 Mar;59(3):434-441. doi: 10.2967/jnumed.117.202945. Epub 2017 Dec 14.

5.

Most of the Intended Management Changes After 68Ga-DOTATATE PET/CT Are Implemented.

Calais J, Czernin J, Eiber M, Fendler WP, Gartmann J, Heaney AP, Hendifar AE, Pisegna JR, Hecht JR, Wolin EM, Slavik R, Gupta P, Quon A, Schiepers C, Allen-Auerbach MS, Herrmann K.

J Nucl Med. 2017 Nov;58(11):1793-1796. doi: 10.2967/jnumed.117.192450. Epub 2017 May 4.

6.

68Ga-PSMA-11 PET/CT Interobserver Agreement for Prostate Cancer Assessments: An International Multicenter Prospective Study.

Fendler WP, Calais J, Allen-Auerbach M, Bluemel C, Eberhardt N, Emmett L, Gupta P, Hartenbach M, Hope TA, Okamoto S, Pfob CH, Pöppel TD, Rischpler C, Schwarzenböck S, Stebner V, Unterrainer M, Zacho HD, Maurer T, Gratzke C, Crispin A, Czernin J, Herrmann K, Eiber M.

J Nucl Med. 2017 Oct;58(10):1617-1623. doi: 10.2967/jnumed.117.190827. Epub 2017 Apr 13.

7.

Reporter gene imaging of targeted T cell immunotherapy in recurrent glioma.

Keu KV, Witney TH, Yaghoubi S, Rosenberg J, Kurien A, Magnusson R, Williams J, Habte F, Wagner JR, Forman S, Brown C, Allen-Auerbach M, Czernin J, Tang W, Jensen MC, Badie B, Gambhir SS.

Sci Transl Med. 2017 Jan 18;9(373). pii: eaag2196. doi: 10.1126/scitranslmed.aag2196.

8.

Human Biodistribution and Radiation Dosimetry of 18F-Clofarabine, a PET Probe Targeting the Deoxyribonucleoside Salvage Pathway.

Barrio MJ, Spick C, Radu CG, Lassmann M, Eberlein U, Allen-Auerbach M, Schiepers C, Slavik R, Czernin J, Herrmann K.

J Nucl Med. 2017 Mar;58(3):374-378. doi: 10.2967/jnumed.116.182394. Epub 2016 Nov 3.

9.

The incidence of thyroid cancer in focal hypermetabolic thyroid lesions: an 18F-FDG PET/CT study in more than 6000 patients.

Barrio M, Czernin J, Yeh MW, Palma Diaz MF, Gupta P, Allen-Auerbach M, Schiepers C, Herrmann K.

Nucl Med Commun. 2016 Dec;37(12):1290-1296.

10.

68Ga-DOTATATE PET/CT Interobserver Agreement for Neuroendocrine Tumor Assessment: Results of a Prospective Study on 50 Patients.

Fendler WP, Barrio M, Spick C, Allen-Auerbach M, Ambrosini V, Benz M, Bluemel C, Grewal RK, Lapa C, Miederer M, Nicolas G, Schuster T, Czernin J, Herrmann K.

J Nucl Med. 2017 Feb;58(2):307-311. doi: 10.2967/jnumed.116.179192. Epub 2016 Aug 18.

11.

SPECT- and PET-based patient-tailored treatment in neuroendocrine tumors: a comprehensive multidisciplinary team approach.

Werner RA, Bluemel C, Lassmann M, Kudlich T, Higuchi T, Lopci E, Allen-Auerbach M, Colletti PM, Rubello D, Zatelli MC, Herrmann K.

Clin Nucl Med. 2015 May;40(5):e271-7. doi: 10.1097/RLU.0000000000000729. Review.

PMID:
25642915
12.

Impact of 68Ga-DOTATATE PET/CT on the management of neuroendocrine tumors: the referring physician's perspective.

Herrmann K, Czernin J, Wolin EM, Gupta P, Barrio M, Gutierrez A, Schiepers C, Mosessian S, Phelps ME, Allen-Auerbach MS.

J Nucl Med. 2015 Jan;56(1):70-5. doi: 10.2967/jnumed.114.148247. Epub 2014 Dec 11.

13.

Perceived misinterpretation rates in oncologic 18F-FDG PET/CT studies: a survey of referring physicians.

Karantanis D, Kalkanis D, Czernin J, Herrmann K, Pomykala KL, Bogsrud TV, Subramaniam RM, Lowe VJ, Allen-Auerbach MS.

J Nucl Med. 2014 Dec;55(12):1925-9. doi: 10.2967/jnumed.114.145607. Epub 2014 Nov 7.

14.

68Gallium- and 90Yttrium-/ 177Lutetium: "theranostic twins" for diagnosis and treatment of NETs.

Werner RA, Bluemel C, Allen-Auerbach MS, Higuchi T, Herrmann K.

Ann Nucl Med. 2015 Jan;29(1):1-7. doi: 10.1007/s12149-014-0898-6. Epub 2014 Aug 20. Review.

15.

Clinical use of bone-targeting radiopharmaceuticals with focus on alpha-emitters.

Wieder HA, Lassmann M, Allen-Auerbach MS, Czernin J, Herrmann K.

World J Radiol. 2014 Jul 28;6(7):480-5. doi: 10.4329/wjr.v6.i7.480. Review.

16.

Oncologic PET/CT interpretation and reporting approaches. Survey in clinical practice.

Karantanis D, Kalkanis D, Allen-Auerbach MS, Herrmann K, Pomykala KL, Bogsrud TV, Lowe VJ, Czernin J.

Nuklearmedizin. 2014;53(2):19-25. doi: 10.3413/Nukmed-0613-13-07. Epub 2014 Jan 29.

PMID:
24473996
17.

Prediction of clinically relevant hyperkalemia in patients treated with peptide receptor radionuclide therapy.

Lapa C, Werner RA, Bluemel C, Lueckerath K, Muegge DO, Strate A, Haenscheid H, Schirbel A, Allen-Auerbach MS, Bundschuh RA, Buck AK, Herrmann K.

EJNMMI Res. 2014 Dec 24;4:74. doi: 10.1186/s13550-014-0074-y. eCollection 2014.

18.

(18)F-FDOPA PET for differentiating recurrent or progressive brain metastatic tumors from late or delayed radiation injury after radiation treatment.

Lizarraga KJ, Allen-Auerbach M, Czernin J, DeSalles AA, Yong WH, Phelps ME, Chen W.

J Nucl Med. 2014 Jan;55(1):30-6. doi: 10.2967/jnumed.113.121418. Epub 2013 Oct 28.

19.

PET/computed tomography and lymphoma.

Allen-Auerbach M, de Vos S, Czernin J.

Radiol Clin North Am. 2013 Sep;51(5):833-44. doi: 10.1016/j.rcl.2013.05.004. Epub 2013 Jul 9. Review.

PMID:
24010908
20.

PET/CT in Oncology: Current Status and Perspectives.

Czernin J, Allen-Auerbach M, Nathanson D, Herrmann K.

Curr Radiol Rep. 2013 May 3;1:177-190. eCollection 2013.

21.

Oncologic 18F-FDG PET/CT: referring physicians' point of view.

Karantanis D, Kalkanis D, Allen-Auerbach M, Bogsrud TV, Subramaniam RM, Danielson A, Lowe VJ, Czernin J.

J Nucl Med. 2012 Oct;53(10):1499-505. doi: 10.2967/jnumed.111.102228. Epub 2012 Aug 23.

22.

Squamous papilloma of the oral cavity and oropharynx on 18F-FDG PET/CT imaging.

Karantanis D, Allen-Auerbach M, Czernin J.

Clin Nucl Med. 2012 May;37(5):e98-9. doi: 10.1097/RLU.0b013e318238f52d.

PMID:
22475925
23.

Sources and resources for oncologists to help answer the question: is PET/CT appropriate for my patient?

Karantanis D, Allen-Auerbach M, Czernin J.

Hell J Nucl Med. 2012 Jan-Apr;15(1):2-8.

PMID:
22413105
24.

Computer-aided quantitative bone scan assessment of prostate cancer treatment response.

Brown MS, Chu GH, Kim HJ, Allen-Auerbach M, Poon C, Bridges J, Vidovic A, Ramakrishna B, Ho J, Morris MJ, Larson SM, Scher HI, Goldin JG.

Nucl Med Commun. 2012 Apr;33(4):384-94. doi: 10.1097/MNM.0b013e3283503ebf. Erratum in: Nucl Med Commun. 2012 Jul;33(7):786.

25.

18F-FDG-PET/CT Imaging as an early survival predictor in patients with primary high-grade soft tissue sarcomas undergoing neoadjuvant therapy.

Herrmann K, Benz MR, Czernin J, Allen-Auerbach MS, Tap WD, Dry SM, Schuster T, Eckardt JJ, Phelps ME, Weber WA, Eilber FC.

Clin Cancer Res. 2012 Apr 1;18(7):2024-31. doi: 10.1158/1078-0432.CCR-11-2139. Epub 2012 Feb 14.

26.

Relationship among glycolytic phenotype, grade, and histological subtype in ovarian carcinoma.

Karantanis D, Allen-Auerbach M, Czernin J.

Clin Nucl Med. 2012 Jan;37(1):49-53. doi: 10.1097/RLU.0b013e3182291e03.

PMID:
22157028
27.

Is there a need for dedicated bone imaging in addition to 18F-FDG PET/CT imaging in pediatric sarcoma patients?

Walter F, Czernin J, Hall T, Allen-Auerbach M, Walter MA, Dunkelmann S, Federman N.

J Pediatr Hematol Oncol. 2012 Mar;34(2):131-6. doi: 10.1097/MPH.0b013e3182282825.

PMID:
22134608
28.

(18)F-FDG PET/CT for monitoring treatment responses to the epidermal growth factor receptor inhibitor erlotinib.

Benz MR, Herrmann K, Walter F, Garon EB, Reckamp KL, Figlin R, Phelps ME, Weber WA, Czernin J, Allen-Auerbach MS.

J Nucl Med. 2011 Nov;52(11):1684-1689. doi: 10.2967/jnumed.111.095257.

29.

3'-deoxy-3'-[18F]fluorothymidine positron emission tomography for response assessment in soft tissue sarcoma: a pilot study to correlate imaging findings with tissue thymidine kinase 1 and Ki-67 activity and histopathologic response.

Benz MR, Czernin J, Allen-Auerbach MS, Dry SM, Sutthiruangwong P, Spick C, Radu C, Weber WA, Tap WD, Eilber FC.

Cancer. 2012 Jun 15;118(12):3135-44. doi: 10.1002/cncr.26630. Epub 2011 Oct 21.

30.

18F-fluorodeoxyglucose uptake of bone and soft tissue sarcomas in pediatric patients.

Walter F, Federman N, Apichairuk W, Nelson S, Phelps ME, Allen-Auerbach M, Walter MA, Czernin J.

Pediatr Hematol Oncol. 2011 Oct;28(7):579-87. doi: 10.3109/08880018.2011.602180.

PMID:
21936620
31.

Breast cancer.

Czernin J, Benz MR, Allen-Auerbach MS.

Methods Mol Biol. 2011;727:141-70. doi: 10.1007/978-1-61779-062-1_9.

PMID:
21331933
32.

Correlation between glycolytic phenotype and tumor grade in soft-tissue sarcomas by 18F-FDG PET.

Benz MR, Dry SM, Eilber FC, Allen-Auerbach MS, Tap WD, Elashoff D, Phelps ME, Czernin J.

J Nucl Med. 2010 Aug;51(8):1174-81. doi: 10.2967/jnumed.109.074229. Epub 2010 Jul 21.

33.

FDG-PET/CT Imaging Predicts Histopathologic Treatment Responses after Neoadjuvant Therapy in Adult Primary Bone Sarcomas.

Benz MR, Czernin J, Tap WD, Eckardt JJ, Seeger LL, Allen-Auerbach MS, Dry SM, Phelps ME, Weber WA, Eilber FC.

Sarcoma. 2010;2010:143540. doi: 10.1155/2010/143540. Epub 2010 Apr 18.

34.

Imaging of CTLA4 blockade-induced cell replication with (18)F-FLT PET in patients with advanced melanoma treated with tremelimumab.

Ribas A, Benz MR, Allen-Auerbach MS, Radu C, Chmielowski B, Seja E, Williams JL, Gomez-Navarro J, McCarthy T, Czernin J.

J Nucl Med. 2010 Mar;51(3):340-6. doi: 10.2967/jnumed.109.070946. Epub 2010 Feb 11.

35.

PET/CT imaging: The incremental value of assessing the glucose metabolic phenotype and the structure of cancers in a single examination.

Czernin J, Benz MR, Allen-Auerbach MS.

Eur J Radiol. 2010 Mar;73(3):470-80. doi: 10.1016/j.ejrad.2009.12.023. Epub 2010 Jan 25. Review.

PMID:
20097498
36.

Quantitative F18-fluorodeoxyglucose positron emission tomography accurately characterizes peripheral nerve sheath tumors as malignant or benign.

Benz MR, Czernin J, Dry SM, Tap WD, Allen-Auerbach MS, Elashoff D, Phelps ME, Weber WA, Eilber FC.

Cancer. 2010 Jan 15;116(2):451-8. doi: 10.1002/cncr.24755. Erratum in: Cancer. 2010 Feb 1;116(3):775.

37.

Measuring response with FDG-PET: methodological aspects.

Allen-Auerbach M, Weber WA.

Oncologist. 2009 Apr;14(4):369-77. doi: 10.1634/theoncologist.2008-0119. Epub 2009 Apr 8. Review.

38.

FDG-PET/CT imaging predicts histopathologic treatment responses after the initial cycle of neoadjuvant chemotherapy in high-grade soft-tissue sarcomas.

Benz MR, Czernin J, Allen-Auerbach MS, Tap WD, Dry SM, Elashoff D, Chow K, Evilevitch V, Eckardt JJ, Phelps ME, Weber WA, Eilber FC.

Clin Cancer Res. 2009 Apr 15;15(8):2856-63. doi: 10.1158/1078-0432.CCR-08-2537. Epub 2009 Apr 7.

39.

PET Imaging of Prostate Cancer Using C-Acetate.

Czernin J, Benz MR, Allen-Auerbach MS.

PET Clin. 2009 Apr;4(2):163-72. doi: 10.1016/j.cpet.2009.05.001. No abstract available.

40.

Comparison of CT, PET, and PET/CT for staging of patients with indolent non-Hodgkin's lymphoma.

Fueger BJ, Yeom K, Czernin J, Sayre JW, Phelps ME, Allen-Auerbach MS.

Mol Imaging Biol. 2009 Jul-Aug;11(4):269-74. doi: 10.1007/s11307-009-0200-9. Epub 2009 Mar 27.

41.

Death from metastatic donor-derived ovarian cancer in a male kidney transplant recipient.

Lipshutz GS, Mihara N, Wong R, Wallace WD, Allen-Auerbach M, Dorigo O, Rao PN, Pham PC, Pham PT.

Am J Transplant. 2009 Feb;9(2):428-32. doi: 10.1111/j.1600-6143.2008.02507.x.

42.

Combined assessment of metabolic and volumetric changes for assessment of tumor response in patients with soft-tissue sarcomas.

Benz MR, Allen-Auerbach MS, Eilber FC, Chen HJ, Dry S, Phelps ME, Czernin J, Weber WA.

J Nucl Med. 2008 Oct;49(10):1579-84. doi: 10.2967/jnumed.108.053694. Epub 2008 Sep 15.

43.

The impact of fluorodeoxyglucose-positron emission tomography in primary staging and patient management in lymphoma patients.

Allen-Auerbach M, de Vos S, Czernin J.

Radiol Clin North Am. 2008 Mar;46(2):199-211, vii. doi: 10.1016/j.rcl.2008.03.004. Review.

PMID:
18619376
44.

Treatment monitoring by 18F-FDG PET/CT in patients with sarcomas: interobserver variability of quantitative parameters in treatment-induced changes in histopathologically responding and nonresponding tumors.

Benz MR, Evilevitch V, Allen-Auerbach MS, Eilber FC, Phelps ME, Czernin J, Weber WA.

J Nucl Med. 2008 Jul;49(7):1038-46. doi: 10.2967/jnumed.107.050187. Epub 2008 Jun 13.

45.

Reduction of glucose metabolic activity is more accurate than change in size at predicting histopathologic response to neoadjuvant therapy in high-grade soft-tissue sarcomas.

Evilevitch V, Weber WA, Tap WD, Allen-Auerbach M, Chow K, Nelson SD, Eilber FR, Eckardt JJ, Elashoff RM, Phelps ME, Czernin J, Eilber FC.

Clin Cancer Res. 2008 Feb 1;14(3):715-20. doi: 10.1158/1078-0432.CCR-07-1762.

46.

Pancreas volumes in humans from birth to age one hundred taking into account sex, obesity, and presence of type-2 diabetes.

Saisho Y, Butler AE, Meier JJ, Monchamp T, Allen-Auerbach M, Rizza RA, Butler PC.

Clin Anat. 2007 Nov;20(8):933-42.

47.

Accuracy of PET/CT in characterization of solitary pulmonary lesions.

Kim SK, Allen-Auerbach M, Goldin J, Fueger BJ, Dahlbom M, Brown M, Czernin J, Schiepers C.

J Nucl Med. 2007 Feb;48(2):214-20.

48.

Evaluation of suspected local recurrence in head and neck cancer: a comparison between PET and PET/CT for biopsy proven lesions.

Halpern BS, Yeom K, Fueger BJ, Lufkin RB, Czernin J, Allen-Auerbach M.

Eur J Radiol. 2007 May;62(2):199-204. Epub 2007 Jan 12.

PMID:
17223003
49.

Improvements in cancer staging with PET/CT: literature-based evidence as of September 2006.

Czernin J, Allen-Auerbach M, Schelbert HR.

J Nucl Med. 2007 Jan;48 Suppl 1:78S-88S. Review.

50.

Novel features in a patient homozygous for the L347P mutation in the PINK1 gene.

Doostzadeh J, Tetrud JW, Allen-Auerbach M, Langston JW, Schüle B.

Parkinsonism Relat Disord. 2007 Aug;13(6):359-61. Epub 2006 Oct 19.

PMID:
17055324

Supplemental Content

Loading ...
Support Center